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Despite major advances in pediatric cancer research, there has been only modest progress
in the survival of children with high risk neuroblastoma (NB) (HRNB). The long term sur-
vival rates of HRNB in the United States are still only 30–50%. Due to resistance that often
develops during therapy, development of new effective strategies is essential to improve
the survival and overcome the tendency of HRNB patients to relapse subsequent to initial
treatment. Current chemotherapy regimens also have a serious limitation due to off target
toxicity. In the present work, we evaluated the potential application of reconstituted high
density lipoprotein (rHDL) containing fenretinide (FR) nanoparticles as a novel approach to
current NB therapeutics.The characterization and stability studies of rHDL-FR nanoparticles
showed small size (<40 nm) and high encapsulation efficiency. The cytotoxicity studies of
free FR vs. rHDL/FR toward the NB cell lines SK-N-SH and SMS-KCNR showed 2.8- and
2-fold lower IC50 values for the rHDL encapsulated FR vs. free FR. More importantly, the
IC50 value for retinal pigment epithelial cells (ARPE-19), a recipient of off target toxicity
during FR therapy, was over 40 times higher for the rHDL/FR as compared to that of free
FR.The overall improvement in in vitro selective therapeutic efficiency was thus about 100-
fold upon encapsulation of the drug into the rHDL nanoparticles.These studies support the
potential value of this novel drug delivery platform for treating pediatric cancers in general,
and NB in particular.
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INTRODUCTION
Neuroblastoma (NB) is one of the most frequently diagnosed
tumors in pediatric patients. The wide spectrum of its clinical
presentation presents a major therapeutic challenge (1). Recently,
a stratification strategy for NB cases has emerged based on estab-
lished clinical and biological criteria as a basis for designing
effective therapeutic regimens for the specific forms of the dis-
ease (2). According to this strategy, approximately 40% of NB
patients are classified as having the high risk form of the disease
(HRNB) (2, 3).
Current treatment of NB patients is largely dependent on
the location of the tumor, the stage of the disease, and the
age of the patient (4, 5). In certain localized cases, surgery
alone is sufficient; however, most often additional therapeutic
interventions, including chemotherapy, radiation, and autolo-
gous stem cell therapy are also employed, especially if metasta-
tic lesions are present (2, 3). The HRNB variant is extremely
resistant to the currently available treatment regimens and often
results in relapses subsequent to the initial phases of the ther-
apy (6, 7). Matthay et al. have reported that the best out-
come for HRNB was achieved with intensive combination of
chemotherapy and surgery, followed by myeloablative therapy
with hematopoietic stem cell rescue, and then differentiation
therapy with isotretinoin (8). Extensive pre-clinical and early
clinical trials for treatment of NB have focused on small-molecule
inhibitors targeting specific genetic pathways, implicated in the
proliferation of NB cells. These include the insulin-like growth
factor I receptor (IGF-IR), phosphoinositide 3-kinase (PI3K),
mammalian target of rapamycin (mTOR), and Akt (9–13). An
alternative approach involves immune therapy utilizing cytokine,
vaccine, antibody, and cellular therapy (14–16). Despite recent
advances in the development of anti-cancer agents and the use
of multi-modal therapeutics for the treatment of HRNB the
morbidity and mortality in this group of patients remains high
(3–5, 17).
Retinoids are analogs of vitamin A, involved in the control
of cell differentiation and proliferation (18). All-trans-retinoic
acid (ATRA), and Fenretinide (FR) (N -(4-hydroxyphenyl) reti-
namide), a synthetic analog of ATRA, have emerged as promising
tumor preventive and therapeutic agents against preneoplastic and
neoplastic lesions (19–21). Both FR and ATRA are antiproliferative
as well as apoptotic in in vivo and in vitro models (22, 23), includ-
ing breast cancer cells (24), ovarian carcinoma cells (25), acute
myeloid leukemia cells (26), and NB cells (27). However, phase
I and II clinical trials have revealed some side effects, including
nyctalopia (night blindness), and dermatological sensitivity (21).
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ATRA has been shown to promote the cellular differentiation of
malignant cells and ATRA-induced remission was demonstrated
in preventing relapse and maintaining remission in NB patients
subsequent to intensive initial therapy (28, 29).
Overall, the current state of the art of NB therapeutics is com-
plex and not yet fully effective, especially in case of high risk
and refractory NB. Consequently, development of advanced treat-
ment modalities is needed, especially to avoid the morbidity of
toxic side effects during chemotherapy. Targeted drug delivery has
been an important focus of recent research, especially for can-
cer chemotherapy (30–33). Numerous projects have focused on
selective tumor delivery of highly toxic drugs that can be trans-
ported to cancer cells and tumors without damage to normal
tissues (34–36). It has been suggested that lipoproteins have struc-
tural properties that enable them to serve as drug delivery vehicles
because of their ability to incorporate hydrophobic drugs into
their micellar core and subsequently facilitate the cellular uptake
of drugs via a tumor selective receptor mediated mechanism (36–
41). Potential of lipoproteins as the “magic bullet” for delivery
of targeted chemotherapy was postulated by Counsell and Poh-
land over 30 years ago (42). Nevertheless, until recently lipopro-
teins have been largely overlooked as drug delivery agents despite
their potential for receptor mediated tumor specific targeting
(36, 37).
The purpose of these studies was to provide proof of concept
for a novel therapeutic approach by encapsulating known anti-NB
agents in a lipoprotein based formulation to achieve selectively
targeted delivery of anti-cancer drugs to NB tumors. Initially,
FR and ATRA were selected as representative drugs based on
the physical/chemical properties, the therapeutic efficacy of these
agents during pre-clinical (43, 44) and clinical studies (45, 46).
FR and ATRA also exhibit an adverse pharmacokinetic profile,
due to their extensive lipophilicity, thus limiting their systemic
application (47). To increase their bioavailability, we incorpo-
rated ATRA and FR into reconstituted high density lipoprotein
(rHDL) nanoparticles and subsequently evaluated some physical
and chemical properties and the anti-NB potential of the resultant
drug formulation.
MATERIALS
Sodium cholate, egg yolk phosphatidylcholine (PC), free choles-
terol (FC), cholesteryl oleate, potassium bromide (KBr), isopropy-
lthiogalactoside (IPTG), dimethyl sulfoxide (DMSO), phenyl-
methylsulfonyl fluoride (PMSF), Triton X-100, thrombin cleavage
kit, FR, and ATRA were purchased from Sigma-Aldrich Corpo-
ration, St Louis, MO, USA. NZYCM was obtained from Teknova,
Hollister, CA, USA. Bacterial protein extraction reagent and bicin-
choninic acid (BCA) protein assay kits were purchased from
Thermo Scientific, Rockford, IL, USA. A histidine-trap (His-Trap)
affinity column was obtained from QIAGEN, Valencia, CA, USA.
Cholesterol and phospholipid estimation kits were obtained from
Wako Pure Chemical Industries Ltd., Richmond, VA, USA. Block
lipid transport-1 (BLT-1) was obtained from Cambridge Corpora-
tion (San Diego, CA, USA) and prepared as 5 mg/ml stock solution
in 100% DMSO. Roswell Park Memorial Institute (RPMI) 1640
media, Iscove’s Modified Dulbecco’s media (IMDM), and fetal
bovine serum (FBS) were obtained from Invitrogen, Carlsbad,
CA USA.
The NB cell lines SK-N-SH and SMS-KCNR were obtained
from Children’s Oncology Group (COG) Cell Culture/Xenograft
Repository, Texas Tech., Lubbock, TX, USA. A retinal pigment
epithelial cell line ARPE-19 was obtained from American Type
Culture Collection (ATCC).
METHODS
PREPARATION OF THE ATRA AND FR CONTAINING NANOPARTICLES
Isolation and purification of recombinant apoA-I
These were performed by the procedure already established (48).
Briefly, BL21(DE3)pLysS cells bearing the pNFXex plasmid were
cultured in 500 ml NZYCM media containing 50µg/ml ampi-
cillin at 37˚C. Upon reaching the culture optical density to 0.6
at 600 nm, ApoA-I synthesis was induced by the addition of
IPTG to a final concentration of 0.5 mM. After 3 h, the bacte-
ria were pelleted by centrifugation and disrupted by lysis buffer
(bacterial protein extraction reagent). The cell lysate was cen-
trifuged at 20,000 g for 30 min at 4˚C. The supernatant frac-
tion was mixed with an equal volume of phosphate-buffered
saline (PBS) containing 6 M guanidine hydrochloric acid (Gn-
HCl), applied to a 5 ml bed volume His-Trap affinity col-
umn, and purified as per manufacturer’s instructions. The N-
terminal His-Tag extension was removed using a thrombin Clean-
Cleave kit (Sigma-Aldrich). The isolated apo A-I was then dia-
lyzed against tris(hydroxymethyl)aminomethane (Tris)-buffered
saline containing 1 mM benzamidine for 16 h at 4˚C. The dia-
lyzed sample was filter-sterilized (0.2µm) and stored at 4˚C
until use.
Preparation of rHDL/ATRA and rHDL/FR complexes
This was accomplished by a procedure developed earlier in our
laboratory (36–38, 40, 41). Briefly, a mixture of egg yolk PC in
CHCl3 with FC, and cholesteryl oleate (CE), was prepared with a
molar ratio of ApoA1:FC:CE:PC= 1:5:1.3:1.15 M. The lipid mix-
ture (PC, FC, and CE) and the drugs (ATRA or FR) and the tracer
[H]3ATRA were dried under nitrogen to a thin film and dispersed
in 60µl DMSO. To this mixture, apo A-I (5 mg) and 140µl sodium
cholate (from a stock of 100 mM) were added and the volume
was made up to 2 ml with Tris-ethylenediaminetetraacetic acid
(EDTA) buffer (10 mM Tris, 0.1 M KCl, 1 mM EDTA pH 8.0). The
final PC to cholate molar ratio was maintained at (1:1.6). The
lipid/protein/cholate mixture was then incubated for 12 h at 4˚C,
followed by dialysis against 2 l of PBS, for 48 h, with three buffer
changes in the first 12 h. The preparations were then centrifuged
at 1000 rpm for 2 min and sterilized using a 0.2µm syringe filter.
The preparations were kept in the dark at 4˚C until used.
OPTIMIZATION OF DRUG LOADING STUDIES WITH rHDL/ATRA
NANOPARTICLES
Reconstituted high density lipoprotein/all-trans-retinoic acid par-
ticles were prepared using increasing initial concentrations of
ATRA from 0.25 to 3 mg/ml while keeping all other ingredients
constant. The percentage ATRA incorporation was determined by
measuring the initial and the final radioactive counts incorporated
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in nanoparticles with the Tri-Carb 2100 TR Liquid Scintillation
Analyzer, East Setauket, NY, USA.
The percentage drug incorporated or drug entrapment effi-
ciency was determined using the Eq. 1:
DEE = {Drug concentration after dialysis/
Drug concentration before dialysis
}× 100 (1)
At each of the drug concentrations, the polydispersity index
(PDI) and diameter of the nanoparticles was established from
using data from dynamic light scattering (DLS) studies as indi-
cated below. PDI was calculated as described earlier (49) using a
span index, which was calculated as per Eq. 2.
Span = (D0.9− D0.1)/D0.5 (2)
whereD0.9,D0.5, andD0.1 are the particle diameters determined,
respectively, at the 90th, 50th, and 10th percentile of the undersized
particle distribution curve.
CHARACTERIZATION OF rHDL/ATRA AND rHDL/FR NANOPARTICLES
Determination of Chemical composition of the rHDL nanoparticles
Cholesterol and phospholipid contents were determined by
respective enzymatic reagent kits (cholesterol E and phospholipid
C), using microtiter plate assays as per manufacturer’s sugges-
tions. Protein determinations were carried out using a BCA protein
assay kit. The percentage ATRA incorporation was determined as
described above. The FR incorporation efficiency was determined
using the initial and final concentration of rHDL/FR formula-
tion using absorption maxima at 340 nm in a spectrophotometer
(Varian Inc., Mulgrave, Australia).
ESTIMATION OF THE SIZE AND MORPHOLOGY OF rHDL/ATRA AND
rHDL/FR NANOPARTICLES
Dynamic light scattering
Particle size analysis of the ATRA and FR loaded rHDL nanopar-
ticles was carried out using a Nanotrac system (Microtrac Inc.,
Montgomeryville, PA, USA) as per manufacturer’s instructions.
The nanoparticles were dispersed in aqueous buffer using an ultra-
sonic water bath (Fisher Scientific, Pittsburgh, PA, USA) for 2 min
and then measured for particle size. The results were reported
as the average of three independent runs with duplicate observa-
tions in each run. The PDI was calculated using Eq. 2 as described
earlier.
Atomic force microscopy
The rHDL-ATRA and rHDL-FR formulation was dialyzed at 4˚C
for 12–18 h against sterile distilled and deionized water to remove
the salts from the solution. It was further diluted 1:5 with sterile
distilled water. Ten microliters of the sample was then placed on
the microscope slide and was allowed to air dry. Sample was then
processed with atomic force microscopy (AFM) on an NTEGRA
Prima scanning probe microscope (NT-MDT, Santa Clara, CA,
USA). Closed-loop feedback semicontact mode was used at a rate
of 0.6 Hz. Scanning started from the 50µm area, going down to
5µm. The images obtained were analyzed with NT-MDT image
analysis software (v 2.2). At least 25 individual particles were mea-
sured from three different positions and the average diameter was
reported.
EFFECT OF FREE AND rHDL ENCAPSULATED FR ON CELL VIABILITY
Culturing of the NB cell line (SK-N-SH and SMS-KCNR), and
retinal pigment cell line (ARPE-19) were carried out according
to procedures and culturing conditions provided by the COG
and ATCC (50, 51). Briefly, the SK-N-SH cells were cultured in
RPMI 1640 containing 2 mM l-Glutamine, 4500 mg/l glucose,
10 mM HEPES, 1500 mg/l Sodium bicarbonate, and 10% FBS.
SMS-KCNR was grown in IMDM with 2 mM l-Glutamine, Insulin
Transferrin Selenium (ITS), and 10% FBS. ARPE-19 cells were
grown in RPMI 1640 containing 2 mM l-Glutamine and 10% FBS.
All the cells were grown in 75 cm2 flasks and incubated at 37˚C and
5% CO2. Cells were passaged using 0.25% trypsin to release the
cells from the flasks, once 80–90% confluency was reached.
PREPARATION OF DRUG FORMULATIONS
Both FR and ATRA stock solutions were prepared at 50 mg/ml
concentration in DMSO. For cytotoxicity studies, the drugs were
prepared by emulsifying in 50% sterile bovine serum albumin
(BSA)/PBS by stirring. Samples for the characterization studies
were prepared by diluting the stock with PBS to achieve equiv-
alent FR molar concentration to that contained by the respec-
tive rHDL/FR nanoparticle samples. (The unencapsulated FR
suspension in BSA is referred to as “free drug.”)
DETERMINATION OF IC50 DOSES
The effect of FR in free drug and rHDL encapsulated particles
was studied using CCK-8 kit (Dojindo Molecular Technologies,
Tabaru, Japan). Briefly, the NB cell lines SMS-KCNR and SK-N-
SH were grown according to procedures and culturing conditions
provided by the ATCC in the irrespective media as stated earlier in
75 cm2 flasks and incubated at 37˚C and 5% CO2 (50, 51). Cells
were passaged using 0.25% trypsin to release the cells from the
flasks, once 80–90% confluency was reached. Cells were counted
using hemocytometer and 5000 cells were seeded per well into
96-well microtiter plates and incubated at 37˚C in 5% CO2 for
24 h to allow the cells to attach to the plates. The free drug and
the rHDL/FR nanoparticles were diluted in serum-free medium
to yield stock solutions of equivalent molar concentrations. Sub-
sequently, aliquots of the stock solutions were added to microtiter
plate wells to achieve the selected concentration range for the
cell viability tests. Controls included cells with media (without
rHDL/drug), cells with empty rHDL particles, and media without
cells with same rHDL/drug and free drug of each concentra-
tion used. Cells were incubated at 37˚C in 5% CO2 for 24 h.
After incubation, 10µL of highly water-soluble tetrazolium salt,
WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-
disulfophenyl)-2H-tetrazolium, monosodium salt] stock solu-
tion (Dojindo) was added to each well. After 3 h of incuba-
tion at 37˚C, the absorbance at 450 nm was measured using
a Bio-Rad 3550 microplate reader (Bio-Rad Laboratories, Her-
cules, CA, USA). Each concentration was studied with six
replicates.
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INHIBITION OF DRUG UPTAKE FROM THE rHDL/FR AND rHDL/ATRA
COMPLEXES
Using human HDL
Neuroblastoma cells SMS-KCNR were plated in 24-well plates
(100,000 cells/well) in their respective media. On the following
day, the monolayers were washed with PBS, pH 7.4, and then
incubated at 37˚C with serum-free medium for 90 min. Cells
were washed with PBS and incubated with a single concentra-
tion of the rHDL/FR complex plus increasing amounts of HDL∗
(0–120µg) in serum-free medium for 90 min. The preparation
was washed once with 1×PBS, pH 3.0 and subsequently with
1×PBS, pH 7.4 respectively. The cells were then lysed with lysis
buffer (50 mm Tris-HCl [pH 8.0], 150 mM NaCl, 0.02% sodium
azide, 100µg/ml PMSF, 1µg/ml aprotinin, and 1% Triton X-100).
The lysate was centrifuged at 10,000 rpm for 5 min. The pro-
tein content of the lysate was determined by BCA assays. The
FR content and ATRA content was followed by spectrophoto-
metric and radioactivity measurements respectively as described
above. HDL∗ was prepared using ultracentrifugation of fresh
serum in potassium bromide density gradient as reported in the
literature (52).
Using block lipid transport-1
The inhibition of uptake of ATRA was also studied in the presence
of BLT (2-Hexyl-1-cyclopentanone thiosemicarbazone) a known
inhibitor of SR-B1 receptors (53). At 0.4 and 2µM concentration
of BLT in SMS-KCNR by the same procedure as described above.
STABILITY STUDIES
Stability of the nanoparticles at low temperature
The nanoparticles were stored at 4˚C and −20˚C. After a month,
100µl aliquots were removed. The samples were dialyzed, using
dialysis tubing with an 8000 MW cut off, at 4˚C for 18 h. The
FR content and particle size before and after dialysis were deter-
mined spectrophotometrically and by DLS methods respectively
as described above.
Stability to lyophilization
Reconstituted high density lipoprotein/fenretinide particles were
dialyzed against 0.1 M PBS. The nanoparticles were freeze-dried
at −56˚C/0.5 Mbar in a Labconco freeze drier (Labconco Corp.,
Kansas City, MO, USA) until they were completely dry, pro-
ducing a powder. The freeze-dried preparations were stored at
−20˚C for 24 h and then reconstituted in 1×PBS. The FR content
and particle size before and after dialysis were determined spec-
trophotometrically and by DLS methods respectively as described
above.
RESULTS
The aim of this project was to characterize the ATRA and FR
containing rHDL nanoparticles and to evaluate the feasibility for
enhancing the cytotoxic efficacy of FR against NB cells. Because of
its high octanol-water coefficient (XlogP), ATRA was considered
to be an appropriate candidate to be transported by the rHDL
drug delivery system and a model for the incorporation of FR.
The rHDL particles with ATRA were prepared as described ear-
lier (36–38, 40, 41). With increasing the initial concentration of
ATRA from 0.25 to 3 mg/ml, a steady decrease in the percentage
incorporation was observed.
As shown in Figure 1. The highest ATRA incorporation
efficiency of 76.12% was observed at 0.25 mg/ml where as it
progressively reduced to 14.6% at the initial ATRA concentra-
tion of 3 mg/ml. The corresponding particle size at each of the
respective initial drug concentrations showed that at 0.75 mg/ml
the mean particle diameter was smallest (86 nm) as compared
to both extreme initial concentrations of 0.25 mg/ml (102.2 nm)
and 3 mg/ml (167 nm); as estimated by DLS. A similar pattern
was observed with the PDI upon increase in the initial ATRA
concentration where there was an initial decrease in the PDI
with increase in the initial concentration of ATRA from 0.25 to
0.75 mg/ml after which the PDI increased from two to five times
with further increase in the initial concentration of ATRA from
1.25 to 3 mg/ml respectively. Overall the PDI was acceptable at all
particle size at ∼0.1 (considerably below the suggested desirable
range:<0.2).
From these initial studies, 0.75 mg/ml initial concentration of
ATRA in the rHDL nanoparticles was shown to be optimal in
terms of incorporation efficiency and polydispersity. Due to the
structural similarities between ATRA and FR, the same load-
ing conditions were employed for the formulation of rHDL-FR
nanoparticles in subsequent studies.
The chemical composition of the ATRA and FR containing
rHDL nanoparticles is shown in Figure 2. The largest com-
ponent of both rHDL/ATRA and rHDL/FR nanoparticles was
phospholipid (61.4 and 52.34% respectively) followed by pro-
tein/apo A-I (25.7 vs. 34.2%), the respective drugs and choles-
terol. The rHDL/ATRA particles had an ∼12% ATRA content
and the rHDL/FR nanoparticles a 12.5% FR content, similar to
earlier findings with paclitaxel containing rHDL nanoparticles
(38, 40, 41).
The entrapment of efficiency of both rHDL/ATRA and
rHDL/FR nanoparticles were 61.95 and 67.07% respectively
(Figure 3) suggesting that ATRA and FR could both be efficiently
incorporated into rHDL nanoparticles.
The DLS measurement of the size distribution of retinoid
nanoparticles are presented in Figures 4A,B. The size of
rHDL/ATRA ranged from 48 to 91 nm with average of 86 nm.
The rHDL/FR particles were found to be distributed in a narrower
FIGURE 1 | Incorporation efficiency of ATRA into rHDL nanoparticles as
a function of initial ATRA concentration.
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FIGURE 2 | Chemical composition of rHDL/ATRA and rHDL/FR particles.
FIGURE 3 | Drug entrapment efficiency of rHDL/ATRA and rHDL/FR
nanoparticles.
range of 22–101.2 nm with average diameter of 38.3 nm. AFM
analysis of the rHDL-ATRA (A) and rHDL-FR (B) nanoparticles
(Figure 5) was consistent with the shape and size distribution of
the particles. The particles were found to be spherical in shape
with the respective mean diameters of 8 and 15 nm for rHDL-
ATRA and rHDL-FR particles, close to values reported for native
HDL (54). The discrepancy between the observed diameters (22
and 86 nm) by DLS vs. 8 and 15 by AFM may be attributed to the
tendency to select zones of clear, uniformly distributed particles
while the larger aggregated particles may be missed with AFM,
while, DLS tends to yield larger particle diameter figures, due to
well known bias for the larger diameter particles (Figures 4A,B).
In addition, the discrepancy between the size estimates by DLS
vs. AFM is likely because DLS measures hydrodynamic diameter,
while AFM measures particle size (55).
The impact of free FR vs. rHDL/FR on survival of the NB cell
lines SK-N-SH and SMS-KCNR and the non-malignant ARPE-19
cell line are shown in Figure 6.
The cytotoxicity assessments of free FR vs. rHDL/FR toward the
NB cell lines SK-N-SH and SMS-KCNR, calculated form the data
shown in Figure 6, yielded respective half maximum inhibitory
concentration (IC50) that were 2.8 and 2 times higher for free FR vs.
the values for the rHDL encapsulated FR formulations (Table 1).
On the other hand the IC50 value of Free FR for the retinal pigment
epithelial cells (ARPE-19) was less than 40 times that of rHDL/FR.
These observations suggest that when FR is delivered via rHDL
FIGURE 4 | Size distribution of rHDL/ATRA (A) and of rHDL/FR (B)
nanoparticles with DLS.
vehicle, it’s toxicity to retinal pigment cells (and perhaps to other
low SR-B1 expressor normal cells) is markedly reduced. These
observations represent improvements of at least 80–112 times in
in vitro therapeutic index, via encapsulation of FR into rHDL
nanoparticles. These findings are also consistent with the selective
impact of rHDL associated anti-cancer agents on malignant vs.
non-malignant cells and tissues, reported earlier (34, 36).
The uptake of both rHDL/ATRA and rHDL/FR nanoparticles
by the NB cell line SMS-KCNR was investigated in the presence
and absence of increasing amounts of human HDL (a competitor
for the SR-B1 receptor) (36, 41). As shown in Figure 7, there
was a gradual decrease in the uptake of ATRA from 89.7, 73,
and 64.4% in response to the inclusion of 10, 20, and 40µg/ml
of human HDL in the incubation mix. The rHDL/FR particles
showed an even sharper decrease in the uptake of FR from 62.65,
49.7, and 18.0% in response to the increasing amounts of human
HDL. These studies indicate that the uptake of ATRA and FR
from the rHDL particles is facilitated by the SR-B1 (HDL) recep-
tor as shown for other anti-cancer agents by our earlier studies
(36, 37, 41).
The inhibition of uptake of ATRA was also studied in the
presence of BLT-1, 2-Hexyl-1-cyclopentanone thiosemicarbazone,
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FIGURE 5 | Morphology of rHDL/ATRA (A) and of rHDL/FR (B) nanoparticles with Atomic Force Microscopy.
FIGURE 6 | Differential cytotoxicity of free fenretinide vs. the rHDL encapsulated drug against non-malignant, ARPE-19 cells (A) and two
neuroblastoma cell lines SMS-KCNR (B) and SK-N-SH (C).
(BLT), a known inhibitor of SR-B1 receptor. At 0.4µM BLT, the
uptake of ATRA was reduced to 26%. These studies (Figure 8)
further support the SR-B1 mediated mechanism of drug delivery
via rHDL nanoparticles.
Stability studies of rHDL-FR particles at 4˚C, −20˚C,
and post-lyophilization resulted in retention of 89, 92, and
94.2% drug when stored for 1 month (Table 2). The parti-
cles appeared clear and uniform with minimal aggregation as
indicated by the DLS patterns before (Figure 4B) and after
storage (Figures 9A–C). These studies indicate that the prepa-
rations are considerably stable and non-leaky at the given
conditions.
DISCUSSION
Systemic toxicity of drugs is a major limitation of the current
chemotherapy approaches for treating cancer in general and
HRNB tumors in particular (3–5, 56). This is an acute prob-
lem in pediatric oncology considering a limited tolerance for
pain and discomfort among pediatric patients. Systemic toxi-
city is generally attributed to the “off target” impact of anti-
cancer agents even when they are preferentially targeted to kill
cancer cells and tumors (57–59). Evasion of systemic toxic-
ity is thus paramount in the pediatric age group because their
immature hepatic and renal systems may limit the dosages of
anti-cancer drugs to be used during chemotherapy. At diagno-
sis, 50% of NB-bearing children exhibit metastatic disease with
poor prognosis (7). There is thus an urgent need for novel
therapeutic approaches with low off target toxicity for treating
HRNB.
Since their discovery, both natural and synthetic retinoids
have been known to play a pivotal role in manipulating cell
and tissue differentiation. Although FR, a synthetic analog of
ATRA, is the most studied anti-cancer retinoid its mechanism of
action in controlling carcinogenesis and metastasis is consider-
ably different from that of ATRA (60). The cytotoxic effect of
FR is known to be due to the production of the sphingolipid,
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Table 1 | Comparative IC50 doses of free and rHDL encapsulated FR on
Neuroblastoma cells and retinal pigment epithelial cells.
Cell type IC50 free fenretinide (µM) IC50 rHDL/fenretinide (µM)
ARPE-19 <1.2 >48
SMS-KCNR 14 5
SK-N-SH 7.2 3.5
FIGURE 7 | Inhibition of uptake of ATRA and FR by in SMS-KCNR
(neuroblastoma) cells from rHDL nanoparticles by human HDL.
FIGURE 8 | Inhibition of ATRA uptake by SMS-KCNR (neuroblastoma)
cells via the SR-B1 inhibitor BLT.
ceramide (61, 62) that acts as a signaling molecule regulat-
ing the differentiation, proliferation, and apoptosis. Ceramide
build up in tumor cells is associated with the accumulation
of reactive oxygen species (ROS), resulting in accelerated cell
death via apoptosis and/or necrosis (63). Although ATRA is
known to be a teratogen (64, 65), it has also been investigated
as a differentiating agent to prevent the relapse of NB, sub-
sequent to an intensive chemotherapy (66, 67). While FR and
ATRA have both been shown to be effective as adjuvants in
NB therapeutics, they both exhibit night blindness as a side
effect (21, 66).
The aim of this project was to characterize the ATRA and FR
containing rHDL nanoparticles and to evaluate the feasibility for
Table 2 | Percentage retention of FR in rHDL-FR nanoparticles when
exposed to different storage conditions.
Storage condition Retention of
FR (%)
Average diameter
by DLS (nm)
4˚C for 1 month 89 39.5
−20˚C for 1 month 92 31.8
Lyophilization at −56˚C 94.2 28.4
FIGURE 9 | Size distribution of rHDL/FR nanoparticles determined by
dynamic light scattering after storage under different conditions. (A)
Storage at 4˚C for 1 month, (B) Storage at −20˚C for 1 month, (C)
Post-Lyophilization.
enhancing the cytotoxic efficacy of FR against NB cells. In addi-
tion, the potential for eventual effective systemic administration
of FR may be explored due to the improvement insolubility and
bioavailability via inclusion of the drug in rHDL nanoparticles. In
the present study, ATRA was used because of its physicochemical
similarities with FR. Also availability of a tritium labeled iso-
tope of ATRA enabled us to perform cellular uptake studies in
the presence of BLT that was not possible with FR. Considering
the teratogenic risks involved with the handling of ATRA, the
specific manufacturer’s safety instructions were strictly followed
throughout the studies. Two of the desirable features of an effec-
tive systemic formulation are to have both small and uniformly
distributed particles. The PDI is a measure of the uniformity of
size of nanoparticles and is based on the concept that scatter-
ing of light from small particles in a fluid media is a function
of their diameter. For drug delivery, the smaller the PDI value,
it is considered to be a more desirable characteristic of the for-
mulation (49). For most nanoparticles the PDI value< 0.2 is
recommended for intravascular use as drug carriers. In our ini-
tial studies, the ATRA preparation at 0.75 mg/ml initial drug
concentration exhibited the particle diameter of 89 nm and the
lowest PDI (0.05). Hence for further studies, 0.75 mg/ml initial
drug concentration was chosen throughout our studies for the
preparation of rHDL/ATRA and rHDL/FR nanoparticles. The
size distribution of the rHDL formulations have shown reason-
able homogeneity as indicated by the low PDI (<0.1). A sin-
gle peak on DLS analysis for both rHDL/ATRA and rHDL/FR
nanoparticles represents a relatively uniform distribution of the
nanoparticles in solution. These patterns are consistent with ear-
lier studies reported for rHDL valrubicin and rHDL paclitaxel
nanoparticles (36, 40).
We studied the growth inhibitory concentrations of FR as a free
drug and as a component of rHDL nanoparticles against a “retinal
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pigment epithelial cell line” ARPE-19. A comparative IC50 data
analysis of NB cell lines and the retinal pigment (non-malignant)
epithelial cell line indicates that when encapsulated into rHDL the
ARPE-19 cells were markedly better protected against FR cytotox-
icity vs. the impact of the free drug. These observations suggest
that the rHDL drug delivery system may be effective in reduc-
ing the side effects of chemotherapy during the treatment of NB
patients with conventional anti-cancer agents. These observations
are consistent with effect of rHDL associated drug particles on
malignant and non-malignant cells reported earlier with other
drugs (34, 36).
The selective tumor uptake of drugs from rHDL nanoparti-
cles via the SR-B1 receptor has previously been demonstrated
for malignant prostate and ovarian cell lines (36, 41, 68). Dur-
ing the present studies, human HDL was added as a competitor
to suppress uptake of FR and ATRA from the rHDL nanoparti-
cles by NB cells (SMS-KCNR). These data (Figure 6) show that
the NB cells tested are likely to overexpress the SR-B1 recep-
tors, as it has been shown for nearly all other malignant cells
and tumors (36, 41, 68). This observation is further supported
by inhibition of drug uptake from the rHDL-ATRA nanoparti-
cles by the NB cells in the presence of BLT, a chemical inhibitor
of SR-B1 function (Figure 7). As mentioned previously, the esti-
mation of FR concentration by spectrophotometry (A340) in the
presence of BLT was not possible due to interference in the FR
absorbance by BLT. Thus these experiments were conducted only
with rHDL-ATRA particles. These observations taken together
indicate that FR and ATRA when encapsulated in rHDL could
be used as an alternative or adjuvant therapy for the treatment
of NB patients resulting in enhanced therapeutic efficacy, with
anticipated reduction in off target toxicity. Clearly, more advanced
studies, especially evaluation of in vivo therapeutic efficacy and
pharmacokinetics will be required before the rHDL model can
be fully evaluated as a useful systemic therapeutic approach for
treating NB patients.
Previous research has indicated that cancer cells have an
enhanced expression of the SR-B1 receptor compared to that
of normal cells (36, 41, 68–70). The rHDL drug delivery has
been shown to be capable of selective delivery of anti-cancer
agents via SR-B1 receptors, leaving normal cells (with either
absent or low in SR-B1 expression) unharmed (36, 41, 68).
Selective, tumor specific delivery of drugs would thus greatly
enhance their therapeutic efficacy, especially due to the antici-
pated reduced off target toxicity, (a major concern in pediatric
oncology) when encapsulated into rHDL nanoparticles. In addi-
tion due to the biocompatibility of rHDL nanoparticles, their
clearance via the reticulo-endothelial system is likely to be pre-
vented thus enhancing the residence time of the drug in the
circulation.
TRANSLATIONAL SIGNIFICANCE
Fenretinide therapy has been employed against refractory NB or
HRNB; however, due to its poor bioavailability and side effects
it has been unsuccessful in phase II clinical trials. In the present
report, we provide preliminary evidence that strongly favors the
rHDL drug delivery system as a unique and effective tool for
treating HRNB, including potential for minimizing side effects.
This report also provides a conceptual background for design-
ing clinical studies for evaluating other anti-cancer agents that
are also anticipated to benefit from the selective delivery features
of the rHDL drug delivery system during chemotherapy. This new
approach, perhaps combined with other treatment modalities may
be successful in improving the survival rates for HRNB.
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